Filing Details
- Accession Number:
- 0000950142-19-000199
- Form Type:
- 13G Filing
- Publication Date:
- 2019-02-11 16:06:54
- Filed By:
- Aisling Capital Ii Lp
- Company:
- Cidara Therapeutics Inc. (NASDAQ:CDTX)
- Filing Date:
- 2019-02-11
- SEC Url:
- 13G Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Aisling Capital II | 1,027,843 | 0 | 1,027,843 | 0 | 1,027,843 | 3.7% |
| Aisling Capital Partners | 1,027,843 | 0 | 1,027,843 | 0 | 1,027,843 | 3.7% |
| Aisling Capital Partners | 1,027,843 | 0 | 1,027,843 | 0 | 1,027,843 | 3.7% |
| Seachaid Pharmaceuticals | 140,621 | 0 | 140,621 | 0 | 140,621 | 0.5% |
| Steve Elms | 0 | 1,027,843 | 0 | 1,027,843 | 1,027,843 | 3.7% |
| Dennis Purcell | 0 | 1,027,843 | 0 | 1,027,843 | 1,027,843 | 3.7% |
| Andrew Schiff | 0 | 1,027,843 | 0 | 1,027,843 | 1,027,843 | 3.7% |
Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
| CIDARA THERAPEUTICS, INC. |
| (Name of Issuer) |
| Common Stock |
| (Title of Class of Securities) |
| 171757107 |
| (CUSIP Number) |
| December 31, 2018 |
| (Date of Event which Requires Filing of this Statement) |
| Check the appropriate box to designate the rule pursuant to which this Schedule is filed. | |
| o | Rule 13d-1(b) |
| o | Rule 13d-1(c) |
| x | Rule 13d-1(d) |
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. 171757107 | SCHEDULE 13G | Page 2 of 13 |
| 1 | NAME OF REPORTING PERSON OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Aisling Capital II, LP | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) x |
| 3 | SEC USE ONLY | |
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER 1,027,843 |
| 6 | SHARED VOTING POWER 0 | |
| 7 | SOLE DISPOSITIVE POWER 1,027,843 | |
| 8 | SHARED DISPOSITIVE POWER 0 |
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,027,843 (See Item 4) | |
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | o |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.7% | |
| 12 | TYPE OF REPORTING PERSON PN |
| CUSIP No. 171757107 | SCHEDULE 13G | Page 3 of 13 |
| 1 | NAME OF REPORTING PERSON OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Aisling Capital Partners, LP | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) x |
| 3 | SEC USE ONLY | |
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER 1,027,843 |
| 6 | SHARED VOTING POWER 0 | |
| 7 | SOLE DISPOSITIVE POWER 1,027,843 | |
| 8 | SHARED DISPOSITIVE POWER 0 |
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,027,843 (See Item 4) | |
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | o |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.7% | |
| 12 | TYPE OF REPORTING PERSON PN |
| CUSIP No. 171757107 | SCHEDULE 13G | Page 4 of 13 |
| 1 | NAME OF REPORTING PERSON OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Aisling Capital Partners, LLC | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) x |
| 3 | SEC USE ONLY | |
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER 1,027,843 |
| 6 | SHARED VOTING POWER 0 | |
| 7 | SOLE DISPOSITIVE POWER 1,027,843 | |
| 8 | SHARED DISPOSITIVE POWER 0 |
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,027,843 (See Item 4) | |
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | o |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.7% | |
| 12 | TYPE OF REPORTING PERSON OO |
| CUSIP No. 171757107 | SCHEDULE 13G | Page 5 of 13 |
| 1 | NAME OF REPORTING PERSON OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Seachaid Pharmaceuticals LLC | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) x |
| 3 | SEC USE ONLY | |
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER 140,621 |
| 6 | SHARED VOTING POWER 0 | |
| 7 | SOLE DISPOSITIVE POWER 140,621 | |
| 8 | SHARED DISPOSITIVE POWER 0 |
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 140,621 (See Item 4) | |
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | o |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.5% | |
| 12 | TYPE OF REPORTING PERSON CO |
| CUSIP No. 171757107 | SCHEDULE 13G | Page 6 of 13 |
| 1 | NAME OF REPORTING PERSON OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Steve Elms | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) x |
| 3 | SEC USE ONLY | |
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION United States |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER 0 |
| 6 | SHARED VOTING POWER 1,027,843 | |
| 7 | SOLE DISPOSITIVE POWER 0 | |
| 8 | SHARED DISPOSITIVE POWER 1,027,843 |
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,027,843 (See Item 4) | |
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | o |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.7% | |
| 12 | TYPE OF REPORTING PERSON IN |
| CUSIP No. 171757107 | SCHEDULE 13G | Page 7 of 13 |
| 1 | NAME OF REPORTING PERSON OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Dennis Purcell | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) x |
| 3 | SEC USE ONLY | |
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION United States |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER 0 |
| 6 | SHARED VOTING POWER 1,027,843 | |
| 7 | SOLE DISPOSITIVE POWER 0 | |
| 8 | SHARED DISPOSITIVE POWER 1,027,843 |
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,027,843 (See Item 4) | |
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | o |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.7% | |
| 12 | TYPE OF REPORTING PERSON IN |
| CUSIP No. 171757107 | SCHEDULE 13G | Page 8 of 13 |
| 1 | NAME OF REPORTING PERSON OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Andrew Schiff | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) x |
| 3 | SEC USE ONLY | |
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION United States |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER 0 |
| 6 | SHARED VOTING POWER 1,027,843 | |
| 7 | SOLE DISPOSITIVE POWER 0 | |
| 8 | SHARED DISPOSITIVE POWER 1,027,843 |
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,027,843 (See Item 4) | |
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | o |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.7% | |
| 12 | TYPE OF REPORTING PERSON IN |
| CUSIP No. 171757107 | SCHEDULE 13G | Page 9 of 13 |
| ITEM 1. | (a) | Name of Issuer: | ||
| | | | ||
| | | Cidara Therapeutics, Inc.. (the “Issuer”) | ||
| | | | ||
| | (b) | Address of Issuer’s Principal Executive Offices: | ||
| | | | ||
| | | 6310 Nancy Ridge Drive, Suite 101, San Diego, CA 92121 | ||
| | | |||
| ITEM 2. | (a) | Name of Person Filing: | ||
| | | | ||
| | | This Schedule 13G (this “Statement”) is being filed by the following persons (collectively, the “Reporting Persons”): | ||
| | | | (i) | Aisling Capital II, LP, a Delaware limited partnership (“Aisling”); |
| | | | (ii) | Aisling Capital Partners, LP, a Delaware limited partnership (“Aisling Partners”) and a general partner of Aisling; |
| | | | (iii) | Aisling Capital Partners LLC, a Delaware limited liability company (“Aisling Partners GP”) and a general partner of Aisling Partners; |
| (iv) | Seachaid Pharmaceuticals LLC, a Delaware corporation (“Seachaid”); | |||
| | | | (v) | Mr. Steve Elms (“Mr. Elms”), a managing member of Aisling Partners GP; |
| | | | (vi) | Mr. Dennis Purcell (“Mr. Purcell”), a managing member of Aisling Partners GP; and |
| | | | (vii) | Mr. Andrew Schiff (“Mr. Schiff”) a managing member of Aisling Partners GP. |
| | (b) | Address of Principal Business Office, or if None, Residence: |
| | | |
| | | The address of the principal business offices of each of the Reporting Persons is 888 Seventh Avenue, 12th Floor, New York, New York 10106. |
| | | |
| | (c) | Citizenship: |
| | | | (i) | Aisling - a Delaware limited partnership |
| | | | (ii) | Aisling Partners - a Delaware limited partnership |
| | | | (iii) | Aisling Partners GP - a Delaware limited liability company |
| (iv) | Seachaid - a Delaware corporation; | |||
| | | | (v) | Mr. Elms - United States |
| | | | (vi) | Mr. Purcell - United States |
| | | | (vii) | Mr. Schiff - United States |
| | (d) | Title of Class of Securities: |
| | | |
| | | Common Stock, par value $0.0001 per share (the “Common Stock”). |
| | | |
| | (e) | CUSIP Number: |
| | | |
| | | 171757107 |
| | | |
| ITEM 3. | IF THIS STATEMENT IS FILED PURSUANT TO §240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A: | |
| | | |
| | (a) | [__] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o) |
| | (b) | [__] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c) |
| | (c) | [__] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c) |
| | (d) | [__] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8) |
| | (e) | [__] An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E) |
| | (f) | [__] An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); |
| CUSIP No. 171757107 | SCHEDULE 13G | Page 11 of 13 |
| ITEM 7. | IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY. |
| Not Applicable. | |
| ITEM 8. | IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP. |
| Not Applicable. | |
| ITEM 9. | NOTICE OF DISSOLUTION OF GROUP |
| Not Applicable. | |
| ITEM 10. | CERTIFICATIONS. |
| Not Applicable. | |
| | |
| CUSIP No. 171757107 | SCHEDULE 13G | Page 12 of 13 |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 11, 2019
| AISLING CAPITAL II, LP | |||
| By: Aisling Capital Partners, LP, As its General Partner | |||
| By: Aisling Capital Partners, LLC, As its General Partner | |||
| By: | /s/ Robert Wenzel | ||
| Name: Robert Wenzel Title: Chief Financial Officer | |||
| AISLING CAPITAL PARTNERS, LP | |||
| By: Aisling Capital Partners, LLC, As its General Partner | |||
| By: | /s/ Robert Wenzel | ||
| Name: Robert Wenzel Title: Chief Financial Officer | |||
| AISLING CAPITAL PARTNERS, LLC | |||
| By: | /s/ Robert Wenzel | ||
| Name: Robert Wenzel Title: Chief Financial Officer | |||
| SEACHAID PHARMACEUTICALS LLC | |||
| By: | /s/ Robert Wenzel | ||
| Name: Robert Wenzel Title: Vice President and Secretary | |||
| STEVE ELMS | |||
| By: | /s/ Steve Elms | ||
| CUSIP No. 171757107 | SCHEDULE 13G | Page 13 of 13 |
| DENNIS PURCELL | |||
| By: | /s/ Dennis Purcell | ||
| ANDREW SCHIFF | |||
| By: | /s/ Andrew Schiff | ||
EXHIBIT INDEX
| Exhibit 1. | Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (previously filed). |